乳酸红霉素-克拉霉素序贯疗法治疗儿童肺炎支原体肺炎疗效及药物经济学分析

Clinical Effect of Clarithromycin Sequential Therapy on Mycoplasma Pneumoniae Pneumonia in Children and Evaluation by Pharmacoeconomics

目的探讨乳酸红霉素-克拉霉素序贯疗法治疗儿童肺炎支原体肺炎的临床效果和药物经济学评价,促进合理用药,降低医疗费用。方法将158例观察对象随机分为2组,序贯组先给予乳酸红霉素静脉滴注4 d,第5天开始改为克拉霉素连续口服10 d;对照组仅以红霉素连续静脉滴注14 d。结果序贯组在有效率、细菌清除率和成本/效益比方面均优于对照组,而总医疗成本和不良反应发生率却低于对照组,差异有统计学意义(P<0.01)。结论儿童肺炎支原体肺炎采用克拉霉素序贯疗法治疗疗效确切、安全、经济、方便,符合药物经济学原则。

Objective To explore the clinical effect of clarithromycin sequential therapy on mycoplasma pneu- moniae pneumonia （MPP） in children,and to evaluate it via pharmacoeconomics in order to promoting rational drug use and reduce medical expenses. Methods One hundred and fifty-eight objects of observation were randomly divided into two groups. The sequential therapy group were treadted with erythromycin for 4 days by intravenous drip,and then with clar- ithromycin for 10 days by oral intake. The control group was treated with erythromycin for 14 days by intravenous drip. Results In the sequential therapy group,the effective rate,bacterial clearance rate and cost-benefit ratio were better than in control group, and the total medical cost and incidence of adverse reactions were lower. The difference was of statistical significance（ P 〈0.01 ）. Conclusion The clarithromycin sequential therapy for MPP in children is proved to be effective, safe,economical,simple,and in conformity with principles of pharmacoeconomics.